A Randomized Phase III Study of Standard Treatment +/- Enoxaparin in Small Cell Lung Cancer

Trial Profile

A Randomized Phase III Study of Standard Treatment +/- Enoxaparin in Small Cell Lung Cancer

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 21 Jul 2017

At a glance

  • Drugs Enoxaparin sodium (Primary) ; Carboplatin; Cisplatin; Etoposide
  • Indications Small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms RASTEN
  • Most Recent Events

    • 21 Jul 2017 Trial has been completed in Sweden (end date: 2017-05-05).
    • 13 Sep 2016 Planned End Date changed from 1 Apr 2017 to 1 Jun 2017.
    • 13 Sep 2016 Planned primary completion date changed from 1 Apr 2016 to 1 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top